Great West Life Assurance Co. Can increased its position in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) by 3.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 106,856 shares of the specialty pharmaceutical company’s stock after buying an additional 3,350 shares during the period. Great West Life Assurance Co. Can owned 0.14% of Impax Laboratories worth $1,715,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in Impax Laboratories by 60.4% in the first quarter. Bank of Montreal Can now owns 53,874 shares of the specialty pharmaceutical company’s stock worth $681,000 after buying an additional 20,288 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Impax Laboratories by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 30,000 shares of the specialty pharmaceutical company’s stock worth $380,000 after buying an additional 300 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Impax Laboratories by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company’s stock worth $102,000 after buying an additional 150 shares in the last quarter. DUPONT CAPITAL MANAGEMENT Corp boosted its stake in Impax Laboratories by 526.6% in the first quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 118,063 shares of the specialty pharmaceutical company’s stock worth $1,493,000 after buying an additional 99,222 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Impax Laboratories by 7.8% in the first quarter. Canada Pension Plan Investment Board now owns 481,200 shares of the specialty pharmaceutical company’s stock worth $6,087,000 after buying an additional 34,700 shares in the last quarter. 86.26% of the stock is currently owned by hedge funds and other institutional investors.

Impax Laboratories, Inc. (NASDAQ:IPXL) opened at 19.00 on Tuesday. The firm’s market cap is $1.36 billion. The stock’s 50 day moving average is $17.85 and its 200 day moving average is $14.72. Impax Laboratories, Inc. has a 12 month low of $7.75 and a 12 month high of $27.29.

Impax Laboratories (NASDAQ:IPXL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The firm had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. During the same quarter in the previous year, the company posted $0.21 earnings per share. The business’s quarterly revenue was up 17.1% compared to the same quarter last year. On average, equities analysts forecast that Impax Laboratories, Inc. will post $0.70 earnings per share for the current year.

WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/impax-laboratories-inc-ipxl-shares-bought-by-great-west-life-assurance-co-can/1528850.html.

A number of equities research analysts recently issued reports on IPXL shares. Vetr cut shares of Impax Laboratories from a “strong-buy” rating to a “strong sell” rating and set a $10.55 price target on the stock. in a research note on Monday, May 1st. Zacks Investment Research raised shares of Impax Laboratories from a “strong sell” rating to a “hold” rating in a research note on Monday, May 8th. Royal Bank Of Canada reissued an “outperform” rating and issued a $62.00 price target (up previously from $10.00) on shares of Impax Laboratories in a research note on Thursday, May 11th. Janney Montgomery Scott reissued a “neutral” rating and issued a $21.00 price target on shares of Impax Laboratories in a research note on Monday, June 12th. Finally, Cantor Fitzgerald started coverage on shares of Impax Laboratories in a research note on Friday, June 16th. They issued an “overweight” rating and a $20.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company’s stock. Impax Laboratories presently has a consensus rating of “Hold” and an average price target of $17.85.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.